
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma is a clinical-stage biopharmaceutical company with a promising CD19 and CD22-targeted ARTEMIS T-cell therapy in development, which addresses treatment challenges for patients with blood cancers and solid tumors. The company's recent completion of an $8M financing and advancement of their therapy into Phase II of its ongoing study, along with onboarding their first Phase II patient, demonstrates strong execution and potential for future success. However, future dilution and potential risks related to clinical, financial, commercial, legal, and intellectual property factors must be considered.
Bears say
Estrella Immunopharma is facing several key challenges that could significantly impact their stock performance. Firstly, their Phase I data for EB103 in aggressive B-cell Non-Hodgkin Lymphoma (NHL), while positive, only covers a small patient population and lacks long-term data. Secondly, there is intense competition in the CAR-T therapy market, and Estrella's technology has yet to be proven in larger clinical trials. Lastly, their valuation is heavily dependent on the success of EB103, with a 30% probability of success and a 30% discount rate, making it a high-risk investment.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares